News Theramex's uterine fibroid drug Yselty backed for NHS use A daily oral therapy for uterine fibroids has been recommended for NHS by NICE, providing a new option for around 30,000 women in England and Wales.
News ObsEva files uterine fibroid drug in US, chasing AbbVie, Myo... Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number of women eligible for this type of
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.